A number of other research analysts have also recently issued reports on the company. Roth Capital initiated coverage on Zafgen in a research note on Friday, April 26th. They set a “buy” rating and a $8.00 price objective on the stock. Cowen reaffirmed a “hold” rating on shares of Zafgen in a research note on Thursday, May 30th. Wedbush reaffirmed a “buy” rating and set a $6.00 price objective on shares of Zafgen in a research note on Thursday, May 30th. Zacks Investment Research lowered shares of Zafgen from a “buy” rating to a “hold” rating in a report on Saturday, July 20th. Finally, Piper Jaffray Companies dropped their target price on shares of Zafgen from $6.00 to $5.00 and set a “hold” rating for the company in a report on Thursday, May 30th. Six equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $7.00.
Shares of NASDAQ:ZFGN opened at $0.95 on Thursday. The company’s 50-day moving average is $1.19. Zafgen has a 12-month low of $0.85 and a 12-month high of $12.35. The company has a current ratio of 7.83, a quick ratio of 7.83 and a debt-to-equity ratio of 0.17.
Several institutional investors have recently bought and sold shares of ZFGN. Gabelli Funds LLC purchased a new stake in shares of Zafgen during the second quarter worth about $26,000. SG Americas Securities LLC boosted its holdings in shares of Zafgen by 73.4% during the second quarter. SG Americas Securities LLC now owns 27,032 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 11,447 shares during the period. Wedbush Securities Inc. boosted its holdings in shares of Zafgen by 118.6% during the second quarter. Wedbush Securities Inc. now owns 76,500 shares of the biopharmaceutical company’s stock worth $91,000 after purchasing an additional 41,500 shares during the period. Alambic Investment Management L.P. purchased a new stake in shares of Zafgen during the first quarter worth about $95,000. Finally, Bank of America Corp DE boosted its holdings in shares of Zafgen by 155.5% during the fourth quarter. Bank of America Corp DE now owns 19,909 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 12,116 shares during the period. Institutional investors own 84.26% of the company’s stock.
Zafgen Company Profile
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
Featured Story: Trading based on a resistance level
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.